capadenoson

Capadenoson is a small molecule, non-nucleoside partial agonist of the adenosine A1 receptor (A1AR), with additional activity at the adenosine A2B receptor. It was developed as an orally active agent for cardiovascular indications and has undergone Phase IIa clinical trials in patients with atrial fibrillation and stable angina. Capadenoson acts by selectively activating the adenosine A1 receptor, which is coupled to G proteins that inhibit adenylyl cyclase activity, leading to reduced heart rate and modulation of norepinephrine release from cardiac presynaptic nerves. The drug was initially developed by Bayer HealthCare but its development status is now discontinued for all known indications[1][2][3][4][5][8].

Other names

Capadenoson [INN]2-amino-6-\[\[2-(4-chlorophenyl)-1,3-thiazol-4-yl\]methylsulfanyl\]-4-\[4-(2-hydroxyethoxy)phenyl\]pyridine-3,5-dicarbonitrileUNII-O519NVW73RUNII-O-519NVW73RUNII-O 519NVW73RO519NVW73RO-519NVW73RO 519NVW73R